Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome

Transplantation
J D EasonA B Cosimi

Abstract

Tumor necrosis factor alpha (TNFa) has been shown to be the primary cytokine responsible for the OKT3-induced acute clinical syndrome (OKT3-ACS). Recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) is a dimer of the p80 TNF receptor, which binds both TNFa and lymphotoxin (LT). Renal allograft recipients undergoing OKT3 therapy for steroid-resistant rejection were randomized to receive OKT3 alone or in combination with TNFR:Fc to determine its safety and efficacy in decreasing the severity of OKT3-ACS and in restoring renal function. Six of 12 patients were given TNFR:Fc prior to each of the first two injections of OKT3. All patients were monitored for manifestations of OKT3-ACS and changes in renal function. In addition, serial serum samples were assayed for TNFa and TNFR:Fc levels (ELISA) and TNFa bioactivity (L929). No adverse side effects were identified in patients receiving TNFR:Fc. Patients treated with TNFR:Fc had significantly fewer symptoms by day 2 of OKT3, and had a lower overall incidence of chills and arthralgias. Renal dysfunction reversed within 24 hr in the TNFR:Fc-treated group in contrast to the 48-72-hr delay in the control group. Antigenic TNFa levels increased in the control group from < 10 p...Continue Reading

References

Feb 1, 1992·The Journal of Experimental Medicine·D AderkaD Wallach
Nov 24, 1988·The New England Journal of Medicine·B H AultS B Murphy
Jun 1, 1988·The American Journal of Medicine·N P ChristiansenB J Kennedy
Oct 1, 1987·The Journal of Experimental Medicine·C P Maury, A M Teppo
Oct 24, 1986·Science·K J TraceyJ D Albert
Mar 30, 1984·Journal of Immunological Methods·D A Flick, G E Gifford
Dec 1, 1981·Transplantation·A B CosimiP S Russell
May 1, 1994·The Journal of Clinical Investigation·C FerranL Chatenoud

❮ Previous
Next ❯

Citations

Nov 14, 1997·Immunology Today·A EiglerS Endres
May 30, 1996·The New England Journal of Medicine·R ThadhaniJ V Bonventre
Jul 20, 2004·Clinical Microbiology Reviews·Ian A ClarkWilliam B Cowden
Oct 13, 2006·Malaria Journal·Ian A ClarkWilliam B Cowden
Apr 5, 2011·Current Opinion in Allergy and Clinical Immunology·Alessandra VultaggioAndrea Matucci
May 19, 2010·Expert Review of Clinical Immunology·Peter J BugelskiEsther Bouman-Thio
Sep 4, 2010·Pharmacology & Therapeutics·Ian A ClarkBryce Vissel
Aug 26, 1998·Rheumatic Diseases Clinics of North America·L W Moreland
Oct 5, 2001·Expert Opinion on Pharmacotherapy·A Alldred
May 15, 2009·Molecular and Cellular Biochemistry·Linda T TranJohn H McNeill
Dec 3, 2014·Expert Review of Clinical Immunology·Aaron J AhearnAndrew M Posselt
May 17, 2003·Blood·Karin ElfleinThomas Hünig
Sep 6, 2003·Journal of Clinical Periodontology·F B MercadoP M Bartold
Feb 11, 2021·Arquivos brasileiros de cardiologia·İsmet DurmuşTuncay Kırış
Aug 10, 2021·The Journal of Allergy and Clinical Immunology. in Practice·Bernard Yu-Hor ThongRik Schrijvers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.